Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 28, 2005 Brian Gorman	Cardinal Changes Course The health care company's warning is a disappointment, but the firm's new focus on returning cash to shareholders is far from bad news.
The Motley Fool January 30, 2006 Brian Gorman	Cardinal Inches Higher The distribution is looking healthier, but Cardinal Health still has work to do. Investors, take note.
The Motley Fool December 10, 2004 Brian Gorman	Cardinal Picks a Lilly Cardinal Health's deal with Lilly suggests the new fee-for-service model is gaining traction.
The Motley Fool January 18, 2005 Brian Gorman	Cardinal Doesn't Get Ruffled The drug distributor's potential loss of Japanese pharmaceutical Eisai will hurt in the short term, but fortunately for investors Cardinal Health continues to plan wisely.
The Motley Fool October 28, 2004 Brian Gorman	Cardinal's Good News: No News The drug wholesaler took a major step toward rehabilitating itself with the release of its 10-K.
The Motley Fool April 7, 2011 Brandon Glenn	"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.
The Motley Fool January 26, 2007 Billy Fisher	A Clean Bill of Health at Cardinal Good results and a key divestiture have this health care company rolling. Investors, take note.
The Motley Fool July 28, 2004 Brian Gorman	Cardinal Watching Cardinal Health continues to be pummeled, but wait patiently, because a buying opportunity could emerge.
The Motley Fool August 5, 2005 Stephen D. Simpson	Can This Cardinal Sing? If Cardinal Health succeeds in its plans to return more capital to shareholders, this could become an interesting income play. This stock is worth keeping an eye on for the future.
The Motley Fool November 7, 2007 Billy Fisher	Cardinal Has Its Wings Clipped Despite a healthy year-over-year pop of 15% in EPS from operations, much of the focus in the first-quarter was shifted to a weak performance by Cardinal's pharmaceutical services segment.
The Motley Fool October 26, 2005 Stephen D. Simpson	Cardinal's Tweet More Sweet Changes at the giant manufacturer, distributor, and service provider in the health-care industry are working out well, but the stock price already reflects it.
The Motley Fool July 1, 2004 W.D. Crotty	Drug Wholesalers Taking a Beating A sharp drop at drug wholesaler Cardinal Health provides a unique buying opportunity.
The Motley Fool January 21, 2005 Rich Duprey	Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all.
The Motley Fool February 21, 2008 Brian Orelli	Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company.
BusinessWeek November 24, 2003 Roger O. Crockett	Cardinal Health, Heal Thyself CEO Walter aims to revive growth, selling high-tech gear and expanding overseas.
The Motley Fool May 2, 2008 Steven Renaldi	Cardinal Health Gets Its Nest in Order Share price rises as investors hope the company is beginning to put some of its troubles behind it.
The Motley Fool June 13, 2006 Ryan Fuhrmann	Cardinal Looks to Deliver Cardinal Health has been through a tumultuous couple of years but appears to have weathered company-specific and industry storms. If the drug distributor can meet its long-term goals, then its stock should represent a long-term solid investment.
The Motley Fool May 6, 2005 W.D. Crotty	McKesson's New Pep Pill The drug wholesaler reports strong fourth-quarter results as it moves to a fee-for-service model.
The Motley Fool May 18, 2005 Brian Gorman	Lilly Launches Automation Eli Lilly's drive to improve efficiency makes the company worth watching.
The Motley Fool May 20, 2004 Tom Taulli	Cardinal Rules of M&A Cardinal Health is upbeat on its latest acquisition, but needs bigger deals to push growth.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool February 4, 2004 Dave Marino-Nachison	Tommy Looks to the Future The fashion brand's fiscal Q3 was better than expected, but many challenges lie ahead.
The Motley Fool October 12, 2004 W.D. Crotty	A Bargain in Drug Distribution? D&K Healthcare Resources' stock surprises investors, but the drop brings a favorable valuation.
The Motley Fool June 27, 2011 Brandon Glenn	Cardinal Health Products Won't Be in Cleveland Medical Mart (or Any Other) Once an early high-profile supporter of the medical mart concept, drug distributor Cardinal Health has had an apparent change of opinion.
Chemistry World July 16, 2010 Matt Wilkinson	Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US.
The Motley Fool March 25, 2011 Brian Orelli	Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool March 4, 2010 Brian Orelli	A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
InternetNews August 5, 2009	Cisco Beats Expectations Despite Sales, Net Drop Like most of the big technology firms, Cisco suffers a big sales and earnings drop, but it still did better than expected.
The Motley Fool November 24, 2010 Brian Orelli	A Manly FDA Approval Eli Lilly has something to be thankful for this week; the Food and Drug Administration approved Axiron, its testosterone replacement therapy.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool August 3, 2006 Ryan Fuhrmann	Cardinal Distributes the Goods The drug wholesaler and distributor has to regain investor confidence and rebuild a track record in a changed industry. So far, so good for 2006. Let's see if any further information can be found once Cardinal submits its 10-K filing to the SEC.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
BusinessWeek August 30, 2004 Gene G. Marcial	PSS Is Really Delivering The Goods When David Smith took the CEO job at PSS World Medical in 2000, sales stood at $160 million. They've since rocketed to $1.35 billion. No wonder industry giants are eyeballing the company: They hope Smith will sell.
The Motley Fool July 23, 2010 Brian Orelli	Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future?
The Motley Fool August 24, 2011 Brandon Glenn	Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge?
InternetNews April 23, 2009 Stuart J. Johnston	Microsoft Earnings Meet Street's Low Expectations The economy's impact is hard to ignore as Microsoft signals continuing weakness.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool August 18, 2005 Rick Aristotle Munarriz	Provide and Conquer Provide Commerce closes a rocky fiscal '05 on a healthy note and looks toward the future. Investors, take note.
IndustryWeek March 1, 2009	Just In Time -- A Breath of Hot Air Memo to President Obama: If lean works for manufacturing, it ought to work for government, too.
The Motley Fool December 3, 2010 Brian Orelli	Merck Smartens Up The acquisition of SmartCells looks like an intelligent move.
The Motley Fool November 8, 2011 Brandon Glenn	Cardinal Health Looks to Build China Business, but Has Long Way to Go For pharmaceuticals distributor Cardinal Health, China represents a world of opportunity.
IndustryWeek November 1, 2008 Jill Jusko	Inflation Outpaces Federal Funding: By the Numbers Academics lose federal R&D dollars for science and engineering.
The Motley Fool November 26, 2010 Brian Orelli	Black Friday Biotech Bargains Drugmakers on sale.
The Motley Fool December 19, 2005 Rich Smith	Foolish Forecast: Progress Report The small enterprise software maker Progress reveals its numbers tomorrow. Investors, take note.
The Motley Fool March 23, 2011 Jordan DiPietro	Should You Buy and Hold Cardinal Health? Does this company have the traits of a good retirement stock?
The Motley Fool August 18, 2010 Brian Orelli	No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals
Finance & Development September 2009 Carlo Cottarelli & Jose Vinals	Looking Ahead Countries must begin now to devise economic strategies to accompany the recovery.